MARKET

INBXV

Inhibrx Inc
INBXV
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-
811.84
131.28
-
Inhibrx Biosciences Advances INBRX-106 Phase 2/3 Trial for Head and Neck Cancer
Reuters · 2d ago
INHIBRX BIOSCIENCES PROVIDES PROGRESS UPDATES ON THE INBRX-106 PROGRAM AND THE EXPANSION COHORTS OF THE OZEKIBART (INBRX-109) PROGRAM
Reuters · 2d ago
Inhibrx Biosciences' Q3 net loss widens, misses EPS estimates
Reuters · 11/14 11:08
Inhibrx Biosciences posts Q3 net loss of $35.3 million
Reuters · 11/14 11:00
INHIBRX REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Reuters · 11/14 11:00
Inhibrx Biosciences Unveils Positive Phase 2 Results for DR5 Agonist Ozekibart in Chondrosarcoma
Reuters · 11/04 21:02
Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
Reuters · 10/30 22:44
Inhibrx Biosciences Reports Positive Phase 3 Results for Ozekibart in Chondrosarcoma
Reuters · 10/23 20:07
More

Webull offers Inhibrx Inc stock information, including NASDAQ: INBXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INBXV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INBXV stock methods without spending real money on the virtual paper trading platform.